Article on Nuvec®’s Potential in RNA Therapeutics
N4 Pharma publishes article on Nuvec® RNA delivery platform potential.
Select text to share a quote on X · sign in to keep highlights & notes in your THAT notes
N4 Pharma plc (AIM: N4P), the UK biotech developing Nuvec®, its proprietary gene delivery system to enable advanced therapies for cancer and other diseases, is pleased to share a new article published on its website: "Reimagining RNA therapeutics: why delivery is the defining challenge-and how Nuvec® is poised to solve it."
The article is on N4 Pharma's interactive investor hub here: https://n4pharma.com/s/25d785
| N4 Pharma plc Nigel Theobald, CEO Luke Cairns, Executive Director Submit your questions directly to the management team via the N4 Pharma Investor Hub | Via N4 Pharma Investor Hub: investors.n4pharma.com https://n4pharma.com/link/yMNQve |
| SP Angel Corporate Finance LLP Nominated Adviser and Joint Broker Matthew Johnson/Jen Clarke (Corporate Finance) Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking) | Tel: +44 (0)20 3470 0470 |
| Turner Pope Investments (TPI) Limited Joint Broker Andy Thacker James Pope | Tel: +44 (0)20 3657 0050 |
| Northstar Communications Limited Investor Relations Sarah Hollins | Tel: +44 (0)113 730 3896 |
About N4 Pharma
N4 Pharma is building out its preclinical data set and working towards first-in-human clinical data to support significant licensing deals for its Nuvec® platform with commercial partners.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.